Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Immunology, Immunotherapy
Erschienen in: Cancer Immunology, Immunotherapy 3/2019

06.02.2019 | Review

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

verfasst von: Ernest Nadal, Bartomeu Massuti, Manuel Dómine, Rosario García-Campelo, Manuel Cobo, Enriqueta Felip

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.
Literatur
1.
2.
Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27CrossRefPubMed
3.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV (2014) Extending survival of stage IV non-small cell lung cancer. Semin Oncol 41:69–92CrossRefPubMed
4.
Melosky B (2014) Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol 4:256PubMedPubMedCentral
5.
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33CrossRefPubMed
6.
7.
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral
8.
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral
9.
Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028CrossRefPubMed
10.
Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846CrossRefPubMed
11.
Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093–2104CrossRefPubMedPubMedCentral
12.
Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T, Ichinose Y (2005) Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 47:85–91CrossRefPubMed
13.
Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, Hizawa N (2007) Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res 27:4457–4460PubMed
14.
Dujon C, Azarian R, Petitpretz P (2009) Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study. Rev Mal Respir 26:952–960CrossRefPubMed
15.
Giroux Leprieur E, Lavole A, Ruppert AM, Gounant V, Wislez M, Cadranel J, Milleron B (2012) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 17:134–142CrossRefPubMed
16.
Van Damme V, Govaerts E, Nackaerts K, Dooms C, Wauters I, Vansteenkiste J (2013) Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer 79:73–76CrossRefPubMed
17.
Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36:1675–1684CrossRefPubMed
18.
19.
Vokes EE, Ready N, Felip E et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965CrossRefPubMed
20.
Crino L, Bidoli P, Delmonte A et al (2016) Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population. J Clin Oncol 34:3067-CrossRef
21.
Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP (2017) KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol 35:abst 9011CrossRef
22.
Herbst R, Garon E, Kim D-W et al (2017) KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thorac Oncol 12:S254–S255CrossRef
23.
Park K, Lewanski C, Gadgeel S et al. 3-year survival and duration of response in randomized phase ii study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). J Thorac Oncol 12:S1840
24.
Gadgeel S, Ciardiello F, Rittmeyer A et al (2017) OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses. J Thorac Oncol 12:S9–S10CrossRef
25.
Garassino M, Rizvi N, Besse B et al (2017) Atezolizumab as 1L therapy for advanced NSCLC in PD-L1—selected patients: updated ORR, PFS and OS data from the BIRCH study. J Thorac Oncol 12:S251–S252CrossRef
26.
Garassino MC, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19:521–536CrossRefPubMedPubMedCentral
27.
Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMed
28.
Abdel-Rahman O (2016) Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol 101:75–85CrossRefPubMed
29.
Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA (2016) The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8:479–488CrossRefPubMed
30.
31.
Mansfield AS, Dong H (2016) Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy. Clin Pharmacol Ther 100:220–222CrossRefPubMed
32.
Ilie M, Long-Mira E, Bence C et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27:147–153CrossRefPubMed
33.
Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27:1953–1958CrossRefPubMedPubMedCentral
34.
McLaughlin J, Han G, Schalper KA et al (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2:46–54CrossRefPubMedPubMedCentral
35.
Teixido C, Karachaliou N, Gonzalez-Cao M, Morales-Espinosa D, Rosell R (2015) Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 12:87–95PubMedPubMedCentral
36.
Kumar R, Collins D, Dolly S, McDonald F, O’Brien MER, Yap TA (2017) Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 41:111–124CrossRefPubMed
37.
38.
de Bruin EC, McGranahan N, Mitter R et al (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256CrossRefPubMedPubMedCentral
39.
McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469CrossRefPubMedPubMedCentral
40.
Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426CrossRefPubMedPubMedCentral
41.
Gandara DR, Kowanetz M, Mok TSK et al (2017) Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L + NSCLC (POPLAR and OAK). Ann Oncol 28:1295OCrossRef
42.
Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33:843 e4–852 e4
43.
44.
Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128CrossRefPubMedPubMedCentral
45.
Schrock A, Sharma N, Peled N et al (2017) Updated dataset assessing tumor mutation burden (TMB) as a biomarker for response to PD-1/PD-L1 targeted therapies in lung cancer (LC). J Thorac Oncol 12:S422CrossRef
46.
Scilla KA, Bentzen SM, Lam VK et al (2017) Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 22:737–742CrossRefPubMedPubMedCentral
47.
Labomascus S, Fughhi I, Bonomi P, Fidler MJ, Borgia JA, Basu S, Hoch MA, Batus M (2017) Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors. J Clin Oncol 35:e14530-eCrossRef
48.
Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7CrossRefPubMed
49.
50.
Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC (2017) Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol 12:403–407CrossRefPubMed
51.
Ardizzoni A, Bidoli P, Chiari R et al (2017) Nivolumab in advanced non-squamous NSCLC patients with KRAS mutations: results from the italian expanded access program (EAP). J Thorac Oncol 12:S1804CrossRef
52.
Gettinger S, Choi J, Mani N et al (2017) Predictive value of measuring somatic mutations and tumor infiltrating lymphocytes for PD-1 axis therapy in non-small cell lung cancer (NSCLC). J Thorac Oncol 12:S430–S431CrossRef
53.
Olugbile S, Bao R, Hensing T, Nakamura Y, Vokes E (2017) Molecular determinants of lack of tumor immune infiltration in NSCLC. J Thorac Oncol 12:S431–S432CrossRef
54.
55.
Sanmamed MF, Perez-Gracia JL, Schalper KA et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Ann Oncol 28:1988–1995CrossRefPubMedPubMedCentral
56.
Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer Immunology. The “cancer immunogram”. Science 352:658–660CrossRefPubMed
57.
Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357CrossRefPubMedPubMedCentral
58.
Park W, Kwon D, Saravia D et al (2018) Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer 19:280–288 e4CrossRefPubMed
59.
Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ (2017) Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 8:8910–8920PubMed
60.
Cousin S, Italiano A (2016) Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res 22:4550–4555CrossRefPubMed
61.
Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33:3193–3198CrossRefPubMedPubMedCentral
62.
Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785–792CrossRefPubMed
63.
Leighl N, Gandhi L, Hellmann M et al (2015) Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol 10:S233
64.
Martínez Bernal G, Mezquita L, Auclin E et al (2017) Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Ann Oncol 28:1323CrossRef
65.
Zhang T, Xie J, Arai S et al (2016) The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7:73068–73079PubMedPubMedCentral
66.
Pillai R, Behera M, Owonikoko T, Kamphorst A, Pakkala S, Belani C, Khuri F, Ahmed R, Ramalingam S (2017) Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC). J Thorac Oncol 12:S253–S254CrossRef
67.
Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688CrossRefPubMedPubMedCentral
68.
Schadendorf D, Larkin J, Postow M, Chiarion-Sileni V, Gonzalez R, Rutkowski P (2016) Efficacy and safety outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity. In: 12th Congress of the European Association of Dermato Oncology, August 31-September 3, 2016; Vienna, Austria
69.
Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45–51CrossRefPubMed
70.
Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212CrossRefPubMedPubMedCentral
71.
Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589PubMed
72.
von Pawel J, Syrigos K, Mazieres J et al (2017) Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann Oncol 28:1314P
73.
Haratani K, Hayashi H, Chiba Y et al (2017) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol
74.
Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15:457–472CrossRefPubMed
75.
Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T (2017) Immune checkpoint inhibitors in lung cancer—an unheralded opportunity? Clin Oncol (R Coll Radiol) 29:207–217CrossRef
76.
Gerber DE, Urbanic JJ, Langer C et al (2017) Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505). Clin Lung Cancer 18:333–339CrossRefPubMed
77.
Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160CrossRefPubMed
78.
Rizvi NA, Hellmann MD, Brahmer JR et al (2016) Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2969–2979CrossRefPubMedPubMedCentral
79.
Juergens R, Hellmann M, Brahmer J et al (2017) First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: checkmate 012 3-year update. J Thorac Oncol 12:S1792–S1793CrossRef
80.
Langer CJ, Gadgeel SM, Borghaei H et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497–1508CrossRefPubMedPubMedCentral
81.
Borghaei H, Langer CJ, Gadgeel S et al (2017) Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Ann Oncol 28:LBA49
82.
Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092CrossRefPubMed
83.
Paz-Ares LG, Luft A, Tafreshi A et al (2018) Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) nonsmall cell lung cancer (NSCLC). American Society of Clinical Oncology, ChicagoCrossRef
84.
Liu SV, Powderly JD, Camidge DR et al (2015) Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33:8030-CrossRef
85.
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34CrossRefPubMedPubMedCentral
86.
Hellmann MD, Rizvi NA, Goldman JW et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18:31–41CrossRefPubMed
87.
Goldman JW, Antonia S, Gettinger S et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced NSCLC: 2-year overall survival and long-term outcomes from checkmate 012. J Clin Oncol 35:Abstr 9093CrossRef
88.
Gubens MA, Sequist LV, Stevenson J et al (2016) Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. J Clin Oncol 34:9027-CrossRef
89.
Antonia S, Goldberg SB, Balmanoukian A et al (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17:299–308CrossRefPubMedPubMedCentral
90.
Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC (2016) A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer 17:232–236.e1CrossRefPubMed
Metadaten
Titel
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
verfasst von
Ernest Nadal
Bartomeu Massuti
Manuel Dómine
Rosario García-Campelo
Manuel Cobo
Enriqueta Felip
Publikationsdatum
06.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 3/2019
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02310-2

Weitere Artikel der Ausgabe 3/2019

Cancer Immunology, Immunotherapy 3/2019 Zur Ausgabe

Clinical Trial Report

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Original Article

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Original Article

Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ

Correction

Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues

Original Article

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

Original Article

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen